Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.17.20 extracted from

  • Kilicarslan, A.; Yavuz, B.; Guven, G.S.; Atalar, E.; Sahiner, L.; Beyazit, Y.; Kekilli, M.; Ozer, N.; Oz, G.; Haznedaroglu, I.C.; Sozen, T.
    Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome (2008), Blood Coagul. Fibrinolysis, 19, 310-314.
    View publication on PubMed

Application

Application Comment Organism
medicine this study aims to assess concomitantly the effects of fenofibrate therapy on thrombin-activatable fibrinolysis inhibitor concentrations and endothelial functions in patients with metabolic syndrome. Twenty-five patients are enrolled in the study. Fenofibrate decreases thrombin-activatable fibrinolysis inhibitor levels and improves endothelial function in metabolic syndrome and, thus, suggests a potential for protection against cardiovascular effects Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
blood plasma
-
Homo sapiens
-

Synonyms

Synonyms Comment Organism
TAFI
-
Homo sapiens
thrombin-activatable fibrinolysis inhibitor
-
Homo sapiens